NMD

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Retrieved on: 
Tuesday, January 3, 2023
Eli Lilly and Company, Bausch Health, CM, AbbVie, University, Eli Lilly, Neuromuscular Disorders, Patient, NYSE, NMD, Fine chemical, Pharmaceutical industry, Pharmacy, Collegium (ancient Rome)

Aarhus, Denmark, 3 January 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that Mike Heffernan has been appointed as Chairman of the Board.

Key Points: 
  • Aarhus, Denmark, 3 January 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that Mike Heffernan has been appointed as Chairman of the Board.
  • Mr. Heffernan succeeds Patrick Vink, who has served as NMD Pharma’s Chairman since 2015.
  • He is the CEO and Chairman of the US-based oncology company Avenge Bio, Inc. which he co-founded in 2019.
  • Mike Heffernan, NMD Pharma’s new Chairman commented: “I feel very privileged to take on this role at such an exciting time for NMD Pharma.

Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors

Retrieved on: 
Tuesday, January 3, 2023
Eli Lilly and Company, Bausch Health, CM, AbbVie, University, Eli Lilly, Neuromuscular Disorders, Patient, NYSE, NMD, Fine chemical, Pharmaceutical industry, Pharmacy, Collegium (ancient Rome)

Aarhus, Denmark, 3 January 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that Mike Heffernan has been appointed as Chairman of the Board.

Key Points: 
  • Aarhus, Denmark, 3 January 2023 – NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that Mike Heffernan has been appointed as Chairman of the Board.
  • Mr. Heffernan succeeds Patrick Vink, who has served as NMD Pharma’s Chairman since 2015.
  • He is the CEO and Chairman of the US-based oncology company Avenge Bio, Inc. which he co-founded in 2019.
  • Mike Heffernan, NMD Pharma’s new Chairman commented: “I feel very privileged to take on this role at such an exciting time for NMD Pharma.

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Retrieved on: 
Wednesday, December 14, 2022
Spinal muscular atrophy, SMN1, Mortality, Myasthenia gravis, Incidence, Novo Holdings A/S, Food, FDA, Fatigue, ODD, NMD, Aarhus University, Weakness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuromuscular Disorders, SMA, Research, Disease, MG, Patient, Pharmaceutical industry

NMD Pharma A/S, is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Key Points: 
  • NMD Pharma A/S, is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.
  • Positive top line data reported from a Phase I/II clinical trial of lead program NMD670 in myasthenia gravis has provided clinical validation of ClC-1 inhibition to restore neuromuscular function.
  • NMD Pharma has raised ~€80 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.
  • Type 1 (0) is the most severe form of the disease with symptoms appearing at birth or in infancy (before birth, type 0).

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

Retrieved on: 
Wednesday, December 14, 2022
Spinal muscular atrophy, SMN1, Mortality, Myasthenia gravis, Incidence, Novo Holdings A/S, Food, FDA, Fatigue, ODD, NMD, Aarhus University, Weakness, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuromuscular Disorders, SMA, Research, Disease, MG, Patient, Pharmaceutical industry

NMD Pharma A/S, is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Key Points: 
  • NMD Pharma A/S, is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.
  • Positive top line data reported from a Phase I/II clinical trial of lead program NMD670 in myasthenia gravis has provided clinical validation of ClC-1 inhibition to restore neuromuscular function.
  • NMD Pharma has raised ~€80 million from investors including Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, Roche Venture Fund, and Jeito Capital.
  • Type 1 (0) is the most severe form of the disease with symptoms appearing at birth or in infancy (before birth, type 0).

Emerging Pipeline Therapeutics Across 6 Rare Neuromuscular Diseases: Strategic Partnering and New Product Development will Enable Better Biologics for Personalized and Targeted Treatment - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, Health, Myasthenia gravis, Sarepta, Therapy, Spinal muscular atrophy, CIDP, DN, US FDA, DMD, Disorder, Myopathy, SMA, Duchenne muscular dystrophy, NMD, Golodirsen, Motor neuron disease, Patient, Amyotrophic lateral sclerosis, US, Degenerative disease, Research, Neuromuscular Disorders, NMDS, ALS, Diabetic neuropathy, Eteplirsen, Muscle, Cramp, Quality of life, Muscle weakness, RNA, Patent, Pharmaceutical industry, Vaccine

Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.

Key Points: 
  • Biologics presents a personalized and targeted method to treat NMDs and is a promising treatment class.
  • This research, "Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis" explores emerging biologics across these six NMDs.
  • Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments.
  • Therefore, biologics are suitably poised to transform the rare NMD landscape with personalized and targeted treatment strategies and will provide life-saving treatment options for fatal neuromuscular conditions.

Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis

Retrieved on: 
Thursday, December 1, 2022
DN, Myasthenia gravis, MG, Cramp, Muscle weakness, RNA, Disorder, Duchenne muscular dystrophy, Therapy, Golodirsen, Patient, Motor neuron disease, Eteplirsen, Neuromuscular Disorders, US, Patent, Muscle, Amyotrophic lateral sclerosis, NMD, Spinal muscular atrophy, DMD, ALS, Diabetic neuropathy, NMDS, SMA, Quality of life, Myopathy, CIDP, US FDA, Degenerative disease, Dietary supplement, Pharmaceutical industry, Health insurance

Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs).

Key Points: 
  • Muscle weakness, cramps, and impaired musculoskeletal functions that occur due to rare defects in nerve and muscle cells characterize neuromuscular disorders (NMDs).
  • The disorders are largely classified as motor neuron diseases, hereditary ataxias, peripheral nerve disorders, neuromuscular junction transmission disorders, and myopathies.
  • Frost & Sullivans research, Emerging Therapeutics for Rare Neuromuscular Diseases: A Pipeline Analysis explores emerging biologics across these six NMDs.Key biologics emerging for these rare NMDs include stem cell therapies, other cell-based treatments, gene therapies, RNA therapeutics, immunotherapies, and other protein/peptide-based treatments.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Skylight Health Group Reports Third Quarter 2022 Financial Results

Retrieved on: 
Wednesday, November 16, 2022
ACO, Risk, APM, Net, FFS, TSX Venture Exchange, FICC, Medicaid, Debenture, Ageing, NMD, Medicare Advantage, Alignment, JV, COVID-19, Growth, Depository Trust Company, EBITDA, Partnership, Skylight, Research, MA, Microbiome, Acquisition, AVM GmbH, Anxiety, OTCQX, Ultimate, MACO, CHS, Renewable energy, Video game, Health insurance, Reinsurance, Security (finance), Pharmaceutical industry, Humana, Central Florida, Adjustment, VBC, Medicare

TORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SLHG; OTCQX:SLHGF) (Skylight Health or the Company), a multi-state primary care management group in the United States, today announced its financial results for the third quarter ended September 30, 2022.

Key Points: 
  • TORONTO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Skylight Health Group Inc. (TSXV:SLHG; OTCQX:SLHGF) (Skylight Health or the Company), a multi-state primary care management group in the United States, today announced its financial results for the third quarter ended September 30, 2022.
  • Adjusted EBITDA loss reduced by 27% from the previous quarter to $3.97 million compared to $5.4 million in the previous quarter.
  • Prad Sekar, CEO of Skylight Health, said, We are pleased with our third quarter results, taking another major step towards achieving the goals we set for 2022.
  • This increase was primarily a result of a full quarter of revenue from the acquisition of NMD in Q2 2022.

AMMC International Conference Concludes in Marrakech

Retrieved on: 
Friday, October 21, 2022
Professional Services, Business, Finance, Partnership, AMMC, International Organization (journal), Jordan Securities Commission, Capital market, HM, NMD, Majesty, International Organization of Securities Commissions, IOSCO, Multimedia, Renewable energy

The Global Capital Markets - Expect the unexpected: a trilemma for capital markets international conference, organized under the High Patronage of HM King Mohammed VI, at the initiative of the Moroccan Capital Market Authority (AMMC), concluded on Thursday, October 20, 2022, in Marrakech.

Key Points: 
  • The Global Capital Markets - Expect the unexpected: a trilemma for capital markets international conference, organized under the High Patronage of HM King Mohammed VI, at the initiative of the Moroccan Capital Market Authority (AMMC), concluded on Thursday, October 20, 2022, in Marrakech.
  • The unique forum hosted a series of high-level debates and discussions to address the question of the current trilemma of capital markets.
  • In her welcome speech, at the opening of the conference, Mrs. Nezha HAYAT, AMMC President said: The AMMC has been at the forefront of the efforts to develop the capital market to better support the economic and social growth of Morocco.
  • The AMMC is the regulatory authority of the Moroccan capital market.

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Retrieved on: 
Tuesday, October 11, 2022
MG, Union, Muscle, Communication, Disease, International Clinical Trials Registry Platform, Seed, Growth, Novo Holdings A/S, Novo Nordisk Foundation, Immunoglobulin G, CHDR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, ODD, Aarhus University, Myasthenia gravis, Food, Degenerative disease, Novo Nordisk, Company, Eyelid, Industry, Administration, NMD, Face, Safety, Neuromuscular Disorders, GMG, Phase, FDA, Fine chemical, Dietary supplement, Pharmaceutical industry

Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.

Key Points: 
  • Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.
  • It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.
  • NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Retrieved on: 
Tuesday, October 11, 2022
MG, Union, Muscle, Communication, Disease, International Clinical Trials Registry Platform, Seed, Growth, Novo Holdings A/S, Novo Nordisk Foundation, Immunoglobulin G, CHDR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Research, ODD, Aarhus University, Myasthenia gravis, Food, Degenerative disease, Novo Nordisk, Company, Eyelid, Industry, Administration, NMD, Face, Safety, Neuromuscular Disorders, GMG, Phase, FDA, Fine chemical, Dietary supplement, Pharmaceutical industry

Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.

Key Points: 
  • Novo Seeds, the company creation arm of Novo Holdings, played an instrumental role in founding and seeding NMD Pharma in 2015, and has since then been a cornerstone investor for the company.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.
  • It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation's assets.
  • NMD Pharma A/S, is a private biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders.